Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines

PARP inhibitors (PARPi), such as Olaparib, have shown promising results in high-grade serous (HGS) epithelial ovarian cancer (EOC) treatment. PARPi sensitivity has been mainly associated with homologous recombination (HR) deficiency, but clinical trials have shown that predicting actual patient resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleury, Hubert, Carmona, Euridice, Morin, Vincent G., Meunier, Liliane, Masson, Jean-Yves, Tonin, Patricia N., Provencher, Diane, Mes-Masson, Anne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522225/
https://www.ncbi.nlm.nih.gov/pubmed/27374179
http://dx.doi.org/10.18632/oncotarget.10308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522225/
https://www.ncbi.nlm.nih.gov/pubmed/27374179
http://dx.doi.org/10.18632/oncotarget.10308

Ejemplares similares